Indication
Juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia is a rare, aggressive hematopoietic malignancy of infancy and early childhood classified as an overlap myelodysplastic and myeloproliferative neoplasm. Read more about Juvenile myelomonocytic leukemia
24 drugs 24 manufacturers
Drugs that treat it
Common Juvenile myelomonocytic leukemia therapies.
AZACITIDINE
AZACITIDINE
AZACITIDINE
AZACITIDINE
AZACITIDINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonJuvenile myelomonocytic leukemia is a rare, aggressive hematopoietic malignancy of infancy and early childhood classified as an overlap myelodysplastic and myeloproliferative neoplasm.
The condition primarily targets the hematopoietic system, resulting in the excessive, clonal proliferation of immature myelomonocytic cells within the bone marrow and peripheral circulation.
Pathophysiologically, it is driven in the vast majority of cases by somatic or germline mutations that cause hyperactivation of the RAS/MAPK signaling pathway and selective hypersensitivity of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor.
Clinically, affected children typically present with persistent peripheral monocytosis, cytopenias, elevated fetal hemoglobin levels, and leukemic organ infiltration manifesting as pronounced hepatosplenomegaly, lymphadenopathy, and cutaneous rashes.
- nih.gov
Juvenile myelomonocytic leukemia is a rare, aggressive hematopoietic malignancy of infancy and early childhood classified as an overlap myelodysplastic and myeloproliferative neoplasm
- nih.gov
Juvenile myelomonocytic leukemia is a rare, aggressive hematopoietic malignancy of infancy and early childhood classified as an overlap myelodysplastic and myeloproliferative neoplasm The condition primarily targets the hematopoietic system, resulting in the excessive, clonal proliferation of immature myelomonocytic cells within the bone marrow and peripheral circulation Pathophysiologically, it is driven in the vast majority of cases by somatic or germline mutations that cause hyperactivation o...
- nih.gov
Juvenile myelomonocytic leukemia is a rare, aggressive hematopoietic malignancy of infancy and early childhood classified as an overlap myelodysplastic and myeloproliferative neoplasm
- rarediseases.org
The condition primarily targets the hematopoietic system, resulting in the excessive, clonal proliferation of immature myelomonocytic cells within the bone marrow and peripheral circulation
- nih.gov
Pathophysiologically, it is driven in the vast majority of cases by somatic or germline mutations that cause hyperactivation of the RAS/MAPK signaling pathway and selective hypersensitivity of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor Clinically, affected children typically present with persistent peripheral monocytosis, cytopenias, elevated fetal hemoglobin levels, and leukemic organ infiltration manifesting as pronounced hepatosplenomegaly, lymphadenopathy, a...
- nih.gov
Pathophysiologically, it is driven in the vast majority of cases by somatic or germline mutations that cause hyperactivation of the RAS/MAPK signaling pathway and selective hypersensitivity of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor
- nih.gov
Clinically, affected children typically present with persistent peripheral monocytosis, cytopenias, elevated fetal hemoglobin levels, and leukemic organ infiltration manifesting as pronounced hepatosplenomegaly, lymphadenopathy, and cutaneous rashes
Personalize your experience
Follow Juvenile myelomonocytic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.